PJ4A Stock Chart & Stats
€7.40
€0.35(4.96%)
At close: 4:00 PM EDT
€7.40
€0.35(4.96%)
Day’s Range― - ―
52-Week Range€5.90 - €15.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€124.12M
Enterprise Value€117.11
Total Cash (Recent Filing)€26.41M
Total Debt (Recent Filing)€349.46K
Price to Earnings (P/E)20.4
Beta0.83
Next Earnings
Oct 05, 2026EPS Estimate
0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.39
Shares Outstanding18,173,565
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio2.73
Price to Book (P/B)7.25
Price to Sales (P/S)15.87
P/FCF Ratio42.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.38
Revenue Forecast (FY)€22.82M
Bulls Say, Bears Say
Bulls Say
High Recurring Revenue MixConversion of one‑time fees to recurring subscriptions (now >98%) materially improves revenue predictability and lowers churn sensitivity. This durable shift supports multi‑period cash flow visibility, easier budgeting for customers and the company, and a scalable SaaS economics base for margin expansion.
Very High And Sustained MarginsSaaS platform economics and disciplined cost control have produced persistently high gross and expanding net margins. These margins drive strong free cash flow potential and provide room for reinvestment, shareholder returns, and cushioning against cyclical top‑line variability over the medium term.
Strong Balance Sheet And Cash GenerationNet cash position and robust operating cash flow give the company durable financial flexibility for buybacks, dividends, R&D or strategic investments. Low leverage reduces refinancing risk and supports capacity to fund multi‑quarter traceability rollouts without pressuring liquidity.
Bears Say
High Supplier Data Error RatesExtremely high error rates in supplier data create persistent remediation costs and require substantial AI and operational work to ensure usable datasets. This raises implementation expense, slows network effects, and may lengthen time‑to‑value for retailer customers, pressuring adoption and unit economics.
Longer Traceability Sales Cycles And Partner UncertaintyTouchless traceability deployments exhibit structural implementation lags and longer sales cycles, delaying revenue recognition and ROI. Reliance on partnerships like Spar to convert pilots into scaled contracts introduces execution risk and timing uncertainty for material revenue ramps over coming quarters.
Receivable Converted To Client Equity Alters Cash ProfileAccepting client stock instead of cash converts predictable receivables into market‑sensitive assets, reducing near‑term cash inflows and increasing counterparty and liquidity risk. This structural change can amplify balance‑sheet volatility and ties part of company value to client operating performance.
ReposiTrak News
PJ4A FAQ
What was ReposiTrak’s price range in the past 12 months?
ReposiTrak lowest stock price was €5.90 and its highest was €15.00 in the past 12 months.
What is ReposiTrak’s market cap?
ReposiTrak’s market cap is €124.12M.
When is ReposiTrak’s upcoming earnings report date?
ReposiTrak’s upcoming earnings report date is Oct 05, 2026 which is in 40 days.
How were ReposiTrak’s earnings last quarter?
ReposiTrak released its earnings results on May 14, 2026. The company reported €0.086 earnings per share for the quarter, beating the consensus estimate of €0.08 by €0.006.
Is ReposiTrak overvalued?
According to Wall Street analysts ReposiTrak’s price is currently Overvalued.
Does ReposiTrak pay dividends?
ReposiTrak does not currently pay dividends.
What is ReposiTrak’s EPS estimate?
ReposiTrak’s EPS estimate is 0.08.
How many shares outstanding does ReposiTrak have?
ReposiTrak has 18,173,565 shares outstanding.
What happened to ReposiTrak’s price movement after its last earnings report?
ReposiTrak reported an EPS of €0.086 in its last earnings report, beating expectations of €0.08. Following the earnings report the stock price went up 0.668%.
Which hedge fund is a major shareholder of ReposiTrak?
Currently, no hedge funds are holding shares in DE:PJ4A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ReposiTrak Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Neutral
DE:PJ4A Sentiment 50%
Sector Average 59%
Sector Average 59%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.26%
12-Months-Change
Fundamentals
Return on Equity
1.05%
Trailing 12-Months
Asset Growth
4.63%
Trailing 12-Months
Company Description
ReposiTrak
ReposiTrak, Inc., a software-as-a-service provider, operates a business-to-business, e-commerce, compliance and traceability, and supply chain management platform in North America. It offers ReposiTrak Compliance Management, which reduces potential regulatory, legal, and criminal risks from its supply chain partners; ReposiTrak Traceability Network, which captures key data elements for designated products; and ReposiTrak Supply Chain Solutions, which enable customers to manage interactions with suppliers. The company also provides business consulting services to suppliers and retailers in the grocery, convenience, and specialty retail sectors. In addition, it provides professional consulting services. The company primarily serves multi-store retail chains, wholesalers, distributors, and their suppliers. ReposiTrak, Inc. has a strategic partnership with Upshop to enable grocery retail traceability. The company was formerly known as Park City Group, Inc. and changed its name to ReposiTrak, Inc. in December 2023. ReposiTrak, Inc. is based in Murray, Utah.
PJ4A Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong margin expansion, balance sheet strength (zero bank debt, ~$26.4M cash), high-quality recurring revenue (now >98%), active capital return programs, patent filings, and early commercial wins for touchless traceability. Key challenges include a flat Q3 revenue due to timing shifts from FDA deadline extensions, a significant increase in tax expense as NOL benefits expire, substantial supplier data quality issues that require AI remediation, and longer sales cycles for traceability with some uncertainty around the Spar Group partnership's near-term revenue impact. Overall, the positives—notably profitability, cash generation, recurring revenue conversion, IP, and shareholder returns—outweigh the near-term timing and execution risks.View all DE:PJ4A earnings summaries